Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999402005> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2999402005 abstract "ABSTRACT Background Data suggest that chemotherapy regimens administered to NSCLC patients in the metastatic setting is not typically associated with febrile neutropenia rates of 20% or greater, therefore, use of WBCGF in this setting should be minimal. National guidelines recommend reduction of chemotherapy dosing in these patients. Our objective was to evaluate the current US Oncology Network utilization of WBCGF in the metastatic setting to determine current practice and associated costs in this palliative chemotherapy setting. Methods We retrospectively identified metastatic NSCLC patients between 7/2006 and 6/2011 using the US Oncology Network EHR database (iKnowMed™). Secondary diagnoses and clinical trials were excluded. Chemotherapy and WBCGF utilization was determined by the number of patients assigned to a 1st or 2nd+ (and beyond) line of therapy (LOT) during the study period. Results During this timeframe, 10,374 patients (female: 44%; median age 67) diagnosed with metastatic NSCLC were identified. Of these, 3284 patients received WBCGF with chemotherapy; where, 2825 patients (33%) were administered 1st LOT and 459 patients (27%) were administered 2nd+ LOT. When reviewing the chemotherapy regimens assigned (regardless of WBCGF administration), the most commonly utilized regimens were: Carboplatin + Paclitaxel +/- Bevacizumab, Pemetrexed containing regimens, Docetaxel containing regimens, Gemcitabine containing regimens, and Vinorelbine. The average estimated cost for these chemotherapy regimens (Medicare Allowable 1Q2012) is $2589/cycle; the average estimated cost of WBCGF usage in the metastatic setting was $1889/dose (Medicare Allowable 1Q2012). Conclusion The American Society of Clinical Oncology has recently identified two opportunities to reduce the cost of care without adversely affecting outcomes (i.e., ineffective chemotherapy at the end of life; the use of WBCGF in palliative chemotherapy where dose reduction is an option). These intersect in this study of NSCLC. These data indicate there is an opportunity to address 40% of the drug costs of NSCLC by the judicious use of protocols using dose reduction as a strategy. Disclosure J.R. Hoverman: I am a medical director for Innovent Oncology. R. Beveridge: I am EVP, Medical Director for McKesson Specialty Health. All other authors have declared no conflicts of interest." @default.
- W2999402005 created "2020-01-23" @default.
- W2999402005 creator A5008773923 @default.
- W2999402005 creator A5013063406 @default.
- W2999402005 creator A5021455895 @default.
- W2999402005 creator A5042661691 @default.
- W2999402005 creator A5087310017 @default.
- W2999402005 date "2012-09-01" @default.
- W2999402005 modified "2023-09-29" @default.
- W2999402005 title "Evaluation of White Blood Cell Growth Factor (WBCGF) Use in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients" @default.
- W2999402005 doi "https://doi.org/10.1016/s0923-7534(20)33895-3" @default.
- W2999402005 hasPublicationYear "2012" @default.
- W2999402005 type Work @default.
- W2999402005 sameAs 2999402005 @default.
- W2999402005 citedByCount "0" @default.
- W2999402005 crossrefType "journal-article" @default.
- W2999402005 hasAuthorship W2999402005A5008773923 @default.
- W2999402005 hasAuthorship W2999402005A5013063406 @default.
- W2999402005 hasAuthorship W2999402005A5021455895 @default.
- W2999402005 hasAuthorship W2999402005A5042661691 @default.
- W2999402005 hasAuthorship W2999402005A5087310017 @default.
- W2999402005 hasBestOaLocation W29994020051 @default.
- W2999402005 hasConcept C121608353 @default.
- W2999402005 hasConcept C126322002 @default.
- W2999402005 hasConcept C143998085 @default.
- W2999402005 hasConcept C2775930923 @default.
- W2999402005 hasConcept C2776256026 @default.
- W2999402005 hasConcept C2776694085 @default.
- W2999402005 hasConcept C2777063308 @default.
- W2999402005 hasConcept C2777240266 @default.
- W2999402005 hasConcept C2777802072 @default.
- W2999402005 hasConcept C2778239845 @default.
- W2999402005 hasConcept C2778336483 @default.
- W2999402005 hasConcept C2778850193 @default.
- W2999402005 hasConcept C2780258809 @default.
- W2999402005 hasConcept C2780350996 @default.
- W2999402005 hasConcept C2781190966 @default.
- W2999402005 hasConcept C2781451048 @default.
- W2999402005 hasConcept C530470458 @default.
- W2999402005 hasConcept C71924100 @default.
- W2999402005 hasConceptScore W2999402005C121608353 @default.
- W2999402005 hasConceptScore W2999402005C126322002 @default.
- W2999402005 hasConceptScore W2999402005C143998085 @default.
- W2999402005 hasConceptScore W2999402005C2775930923 @default.
- W2999402005 hasConceptScore W2999402005C2776256026 @default.
- W2999402005 hasConceptScore W2999402005C2776694085 @default.
- W2999402005 hasConceptScore W2999402005C2777063308 @default.
- W2999402005 hasConceptScore W2999402005C2777240266 @default.
- W2999402005 hasConceptScore W2999402005C2777802072 @default.
- W2999402005 hasConceptScore W2999402005C2778239845 @default.
- W2999402005 hasConceptScore W2999402005C2778336483 @default.
- W2999402005 hasConceptScore W2999402005C2778850193 @default.
- W2999402005 hasConceptScore W2999402005C2780258809 @default.
- W2999402005 hasConceptScore W2999402005C2780350996 @default.
- W2999402005 hasConceptScore W2999402005C2781190966 @default.
- W2999402005 hasConceptScore W2999402005C2781451048 @default.
- W2999402005 hasConceptScore W2999402005C530470458 @default.
- W2999402005 hasConceptScore W2999402005C71924100 @default.
- W2999402005 hasLocation W29994020051 @default.
- W2999402005 hasOpenAccess W2999402005 @default.
- W2999402005 hasPrimaryLocation W29994020051 @default.
- W2999402005 hasRelatedWork W126865085 @default.
- W2999402005 hasRelatedWork W1604277535 @default.
- W2999402005 hasRelatedWork W166645962 @default.
- W2999402005 hasRelatedWork W2036842629 @default.
- W2999402005 hasRelatedWork W2044715315 @default.
- W2999402005 hasRelatedWork W2065798234 @default.
- W2999402005 hasRelatedWork W2125423043 @default.
- W2999402005 hasRelatedWork W2138193535 @default.
- W2999402005 hasRelatedWork W2192942249 @default.
- W2999402005 hasRelatedWork W2267680549 @default.
- W2999402005 hasRelatedWork W2283102211 @default.
- W2999402005 hasRelatedWork W2340641404 @default.
- W2999402005 hasRelatedWork W2460390295 @default.
- W2999402005 hasRelatedWork W2538260229 @default.
- W2999402005 hasRelatedWork W2597310298 @default.
- W2999402005 hasRelatedWork W2802126868 @default.
- W2999402005 hasRelatedWork W2806494449 @default.
- W2999402005 hasRelatedWork W2885015925 @default.
- W2999402005 hasRelatedWork W2896588336 @default.
- W2999402005 hasRelatedWork W3046960882 @default.
- W2999402005 isParatext "false" @default.
- W2999402005 isRetracted "false" @default.
- W2999402005 magId "2999402005" @default.
- W2999402005 workType "article" @default.